KRAS and colorectal cancer: The treatment with cetuximab in the Satellite trial might have interfered, as mutated KRAS is a biomarker of resistance to cetuximab in colorectal cancer [13], however in neither the FLEX- nor BMS099 trial where cetuximab was given combined with chemotherapy in stage IV disease, a correlation between KRAS and response to cetuximab in NSCLC [9] was observed.